Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials

Digestive Diseases and Sciences

Volumn 61, Issue 8, 2016, Pages 2357-2372

  Camilleri, Michael ^a   Piessevaux, Hubert ^b   Yiannakou, Yan ^c   Tack, Jan ^d   Kerstens, René ^e   Quigley, Eamonn M M ^f   Ke, Mei Yun ^g   Da Silva, Susana ^h   Levine, Amy ⁱ  

^a Mayo Clinic College of Medicine   (United States)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c Department of Occupational Health and Wellbeing   (United Kingdom)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e Orion Statistical Consulting BV   (Netherlands)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^h Shire   (Belgium)

ⁱ SHIRE   (United States)

Author keywords

Constipation; Efficacy; Prucalopride; Safety

Indexed keywords

PLACEBO; PRUCALOPRIDE; BENZOFURAN DERIVATIVE; SEROTONIN 4 AGONIST;

ABDOMINAL PAIN; ADVERSE OUTCOME; ARTICLE; BLOATING; CHRONIC CONSTIPATION; DEFECATION DISORDER; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HARD FECES; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; INCIDENCE; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; TREATMENT OUTCOME; ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; CONSTIPATION; DOUBLE BLIND PROCEDURE; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZOFURANS; CHRONIC DISEASE; CLINICAL TRIALS, PHASE III AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN 5-HT4 RECEPTOR AGONISTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84964078937     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-016-4147-9     Document Type: Article

References (42)

1. Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther. 2010;31:938–949.
2. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25:599–608.
3. Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol. 2005;100:936–971.
4. Bassotti G, Villanacci V. Slow transit constipation: a functional disorder becomes an enteric neuropathy. World J Gastroenterol. 2006;12:4609–4613.
5. Krishnamurthy S, Schuffler MD, Rohrmann CA, Pope CE II. Severe idiopathic constipation is associated with a distinctive abnormality of the colonic myenteric plexus. Gastroenterology. 1985;88:26–34.
6. Singh S, Heady S, Coss-Adame E, Rao SS. Clinical utility of colonic manometry in slow transit constipation. Neurogastroenterol Motil. 2013;25:487–495.
7. Dinning PG, Wiklendt L, Maslen L, et al. Colonic motor abnormalities in slow transit constipation defined by high resolution, fibre-optic manometry. Neurogastroenterol Motil. 2015;27:379–388.
8. Wattchow D, Brookes S, Murphy E, et al. Regional variation in the neurochemical coding of the myenteric plexus of the human colon and changes in patients with slow transit constipation. Neurogastroenterol Motil. 2008;20:1298–1305.
9. He CL, Burgart L, Wang L, et al. Decreased interstitial cell of Cajal volume in patients with slow-transit constipation. Gastroenterology. 2000;118:14–21.
10. Johnson DA. Treating chronic constipation: how should we interpret the recommendations? Clin Drug Investig. 2006;26:547–557.
11. Dinning PG, Hunt L, Patton V, et al. Treatment efficacy of sacral nerve stimulation in slow transit constipation: a two-phase, double-blind randomized controlled crossover study. Am J Gastroenterol. 2015;110:733–740.
12. Corsetti M, Tack J. New pharmacological treatment options for chronic constipation. Expert Opin Pharmacother. 2014;15:927–941.
13. Tonini M. 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors. Neurogastroenterol Motil. 2005;17:637–642.
14. 4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20:99–112.
15. Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35:745–767.
16. Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol. 2007;554:98–105.
17. European Medicines Agency. Annex I. Summary of product characteristics Resolor. 2014.
18. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–2354.
19. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58:357–365.
20. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation—a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29:315–328.
21. Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil. 2012;24:999-e541.
22. Piessevaux H, Corazziari E, Rey E, et al. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride. Neurogastroenterol Motil. 2015;27:805–815.
23. Yiannakou Y, Piessevaux H, Bouchoucha M, et al. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol. 2015;110:741–748.
24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
25. 4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther. 2014;39:239–253.
26. Tack J, Quigley E, Camilleri M, Vandeplassche L, Kerstens R. Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis. United European Gastroenterol J. 2013;1:48–59.
27. Ke M, Tack J, Quigley EM, et al. Effect of prucalopride in the treatment of chronic constipation in Asian and non-Asian women: a pooled analysis of 4 randomized, placebo-controlled studies. J Neurogastroenterol Motil. 2014;20:458–468.
28. Bharucha AE. High amplitude propagated contractions. Neurogastroenterol Motil. 2012;24:977–982.
29. Bassotti G, Gaburri M, Imbimbo BP, et al. Colonic mass movements in idiopathic chronic constipation. Gut. 1988;29:1173–1179.
30. Dinning PG, Di Lorenzo C. Colonic dysmotility in constipation. Best Pract Res Clin Gastroenterol. 2011;25:89–101.
31. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120:354–360.
32. Camilleri M. New treatment options for chronic constipation: mechanisms, efficacy and safety. Can J Gastroenterol. 2011;25:29B–35B.
33. Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol. 2009;296:G295–G301.
34. Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1084–1092.
35. Manini ML, Camilleri M, Goldberg M, et al. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil. 2010;22:42–49.
36. 4 agonist with high intrinsic activity, in chronic idiopathic constipation—a 4-week, randomized, double-blind, placebo-controlled, dose–response study. Aliment Pharmacol Ther. 2010;32:1102–1112.
37. Camilleri M, Vazquez-Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil. 2007;19:30–38.
38. Shin A, Acosta A, Camilleri M, et al. A randomized trial of 5-hydroxytryptamine-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2014;13:701–708.
39. Quigley EM. Cisapride: what can we learn from the rise and fall of a prokinetic? J Dig Dis. 2011;12:147–156.
40. Chan KY, de Vries R, Leijten FP, et al. Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries. Eur J Pharmacol. 2009;619:61–67.
41. Mendzelevski B, Ausma J, Chanter DO, et al. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol. 2012;73:203–209.
42. Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil. 2009;21:1256-e117.